Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) will provide a business update and report third quarter 2025 financial results on November 4, 2025. The company will host a conference call and live webcast at 4:30 pm ET / 1:30 pm PT. Participants can dial 1-800-717-1738 (toll-free U.S.) or 1-646-307-1865 (international), or join via the instant telephone access link and the company’s investor relations webcast page. A replay of the webcast will be available on the Corvus website for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, CRVS declined 3.44%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.5% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $21M from the company's valuation, bringing the market cap to $586M at that time.
Data tracked by StockTitan Argus on the day of publication.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 4, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2025 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When will Corvus (CRVS) report third quarter 2025 results?
How can investors join the Corvus (CRVS) November 4, 2025 conference call?
Where can I watch the Corvus (CRVS) live webcast for the Q3 2025 update?
Will there be a replay of the Corvus (CRVS) November 4, 2025 webcast?
What time is the Corvus (CRVS) call for international participants on November 4, 2025?
